vTv Therapeutics
VTVT
48 hedge funds and large institutions have $13.8M invested in vTv Therapeutics in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 9 reducing their positions, and 7 closing their positions.
180% more capital invested
Capital invested by funds: $4.94M → $13.8M (+$8.87M)
144% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 9
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
9% more funds holding
Funds holding: 44 → 48 (+4)
0.08% more ownership
Funds ownership: 0.12% → 0.21% (+0.08%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.73M |
| 2 |
Two Sigma Investments
New York
|
+$927K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$442K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$435K |
| 5 |
Two Sigma Advisers
New York
|
+$372K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$140K |
| 2 |
VF
Virtu Financial
New York
|
-$70K |
| 3 |
Squarepoint
New York
|
-$61K |
| 4 |
N
Natixis
Paris,
France
|
-$42K |
| 5 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$30K |
VTVT Hedge Fund Activity: Q1 2021 in Review
48 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2021, worth a combined $13.8M — up 180% from $4.94M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new VTVT positions and 7 closed out — a net gain of 5 holders — while 22 added to existing stakes and 9 trimmed.
The largest buyer was Nuveen, adding an estimated $1.73M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $140K sold.
- 48 institutional investors held vTv Therapeutics (VTVT) as of Q1 2021, up from 44 in Q4 2020.
- Funds reported $13.8M of vTv Therapeutics stock for Q1 2021, up 180% quarter-over-quarter.
- 12 funds opened new vTv Therapeutics positions in Q1 2021 and 7 closed out, a net change of +5 holders.
- The largest vTv Therapeutics buyer in Q1 2021 was Nuveen, an estimated $1.73M added.
- The largest vTv Therapeutics seller in Q1 2021 was Renaissance Technologies, an estimated $140K sold.
Based on aggregated 13F filings for Q1 2021.